TipRanks
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
US Market
OCUL
Ocular Therapeutix
RESEARCH TOOLSreports
Want to see OCUL full AI Analyst Report?

Ocular Therapeutix (OCUL) Stock News & Sentiment

1,666 Followers
Analyst Maintains Buy Rating on Axpaxli with $14 Price Target, Citing Large Retinal Market Opportunity and Manageable Regulatory Risk
Premium
Ratings
Analyst Maintains Buy Rating on Axpaxli with $14 Price Target, Citing Large Retinal Market Opportunity and Manageable Regulatory Risk
1d ago
OCUL
Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
Premium
Ratings
Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
14d ago
OCUL
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
Premium
Ratings
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
17d ago
OCUL
3 Best Stocks With 150%+ Upside to Buy This Week, According to Analysts
Premium
Market News
3 Best Stocks With 150%+ Upside to Buy This Week, According to Analysts
22d ago
OCUL
ONDS
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
Premium
Ratings
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
27d ago
OCUL
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
Premium
Ratings
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
27d ago
OCUL
3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
Premium
Market News
3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
1M ago
GMAB
OCUL
More OCUL News >

OCUL News on the Web

Ocular Therapeutix initiated with a Buy at UBS
TipRanks News
Bullish
Analysts Call Ocular Selloff Overdone As Shares Bounce
TipRanks News
Neutral
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
Insider Monkey
Neutral
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
TipRanks News
Bullish
Ocular Therapeutix Crumbles As Profit-Takers Flee Rally
TipRanks News
Neutral
Ocular Therapeutix Tumbles As Rally Unravels And Risks Loom
TipRanks News
Neutral
Ocular Therapeutix Soars On Drug Milestone And Big Buyer
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
OCUL
Sector Average
Media Buzz
This Week3 articles
Weekly Average4.25 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OCUL’s Media Buzz Sentiment?
3 articles about OCUL were published this week. In an average week, 4.25 articles are published.
    What is OCUL’s weekly average amount of articles?
    In an average week, 4.25 articles about OCUL are published.
      What is OCUL’s News Sentiment?
      100% of articles about OCUL were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        IQVIQVIA Holdings
        GILDGilead Sciences
        ABBVAbbVie
        VRTXVertex Pharmaceuticals
        NVSNovartis
        Showing the stocks with the most bullish news sentiment over the past week